TH-17 PHENOTYPE OF JUVENILE IDIOPATHIC ARTHRITIS

Urgency. Juvenile idiopathic arthritis (JIA) remains one of the most urgent issues of pediatric rheumatology due to incapacitation at early stages of the disease. It has been established that the first years of arthritis are key in the aspect of progression of the pathological process. Despite significant progress in treating JIA with genetically engineered biopharmaceuticals, some patients do not respond to such a therapy and thus aggravate the disease course. The study was aimed at improving diagnosis and treatment of children with JIA by means of analyzing the main immunological factors Th17, suggesting methods of differentiating lymphocytes and developing recommendations on assessing prognosis of the disease's course and outcomes. Methods. The study included 108 2–18-yearsold children with various forms of JIA. The control group was comprised of 18 conventionally healthy 6–17-years-old children with unburdened heredity regarding autoimmune diseases and without any clinical symptoms of diseases. The total T helper population and subpopulations thereof (naive Th cells and Th memory cells, double-positive Th cells), subpopulations of Th17 cells and anti-inflammatory cytokines (IL 1β, IL 6, IL 17A and TNF α) in the peripheral blood were analyzed in all the patients, including the control group. Results. The levels of Th17 memory cells and anti-inflammatory cytokines (IL 1β, IL 6 and IL 17A) were significantly higher in children with enthesitis-associated arthritis (HLA B27+ juvenile ankylosing spondyloarthritis) and systemic JIA. The level of Th17 cells and high blood level of IL 17A affect development of an active disease; simultaneous increase in IL 6 results in higher risk of osteochondral destruction in children with JIA. Conclusion. According to the immunological data, there are at least 2 JIA phenotypes: Th17-dependent and Th17-independent. Th17-dependent JIA is characterized by the most adverse course of the disease and high risk of osteoarticular destruction, which is why children require earlier prescription of genetically engineered biopharmaceuticals. By contrast, Th17-independent phenotype features a more favorable disease outcome and low risk of osteoarticular destruction.

juvenile idiopathic arthritis, arthritis, Th17 cells, IL 17A, IL 1β, IL 6, TNF α, cytokines, enthesitis-associated arthritis, HLA B27, systemic arthritis

1. Alexeeva E.I., Litvitskii P.F. Yuvenil'nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya [Juvenile Rheumatoid Arthritis: Etiology, Pathogenesis, Clinical Algorithms for Diagnosis and Treatment]. Moscow, VEDI, 2007. 368 p.

2. Wallace C.A. Current management of juvenile idiopathic arthritis. Best Practice and Research Clinical Rheumatology. 2006; 20 (2): 279−300.

3. Wu Q., Pesenacker A.M., Stansfield A., King D., Barge D., Foster H.E., Abinun M., Wedderburn L.R. Immunological characteristics and T cell receptor clonal diversity in children with systemic juvenile idiopathic arthritis undergoing T cell depleted autologous stem cell transplantation. Immunology. 2014; 142 (2): 227−36.

4. Rokhlina F.V., Novik G.A., Kalinina N.M., Bychkova N.V., Filippova Yu.N., Zaraiskii M.I. Effect of MDR1 gene polymorphism S3435E on the effectiveness of treatment of juvenile idiopathic arthritis. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 10 (5): 46−51.

5. Kurebayashi Y., Nagai S., Ikejiri A., Koyasu S. Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells. Genes to Cells. 2013; 18 (4): 247–65.

6. Duurland C.L., Wedderburn L.R. Current developments in the use of biomarkers for juvenile idiopathic arthritis. Current Rheumatology Report. 2014; 16 (3): 406−11.

7. Yamaguchi M. The role of regucalcin in bone homeostasis: involvement as a novel cytokine. Integrative Biology (Cambridge). 2014; 6 (3): 258−66.

8. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation оf interleukin 17-producing human T helper cells. Nature immunology. 2007; 8 (9): 942−49.

9. Acosta-Rodriguez E.V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., Sallusto F., Napolitani G. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nature Immunology. 2007; 8(9): 639–46.

10. Almanzar G., Zlamy M., Koppelstaetter C., Brunner A., Jeller V., Duftner Ch., Dejaco C., Brunner J., Prelog M. Increased replication of CD4+ naive T cells and changes in T cell homeostasis in a case of acute exacerbation of juvenile idiopathic arthritis: a case comparison study. Journal of Medical Case Reports. 2013; 7 (135): 1011−19.

11. Weitzmann M.N. The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica (Cairo). 2013. Р. 705−11.

12. Lazic E., Jelusic M., Grcevic D., Marusic A., Kovacic N. Osteoblastogenesis from synovial fluid-derived cells is related to the type of severity of juvenile idiopathic arthritis. Arthritis Research and Therapy. 2012; 14 (3): R139.

13. Petty R.E., Southwood T.R., Manners P. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. Journal of Rheumatology. 2004; 31 (2): 390–92.

14. Corrado A., Neve A., Maruotti N., Cantatore F.P. Bone Effects of Biologic Drugs in Rheumatoid Arthritis. Clinical and Developmental Immunology. 2013. Р. 105−12.

15. Hueber W., Sands B.E., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins P.D, Wehkamp J. Secukiunumab a human anti-IL-17 monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomized, double-blind, placebo-controlled trial. Gut. 2012; 61 (12): 1693−1700.